evaluation of efficacy and safety of fostamatinib monotherapy compared with adalimumab monotherapy in patients with rheumatoid arthritis (ra)

Conditions: Rheumatoid Arthritis

Summary: the purpose of the study is to evaluate the improvements in signs and symptoms of rheumatoid arthritis (ra) for fostamatinib compared to placebo or adalimumab in patients who are disease-modifying anti-rheumatic drug (dmard) naïve, dmard intolerant or have had an inadequate response to dmards. the study will last for approximately six months

sub-study: full title: optional genetic research date: 10 september 2010 version: 1 objectives: to collect and store, with appropriate consent , dna samples for future exploratory research into genes/genetic variation that may influence response (ie, absorption, distribution, metabolism and excretion, safety, tolerability and efficacy) to fostamatinib disodium and/or adalimumab; and/or susceptibility to, progression of and prognosis of ra the main study recruitment is complete, and sub study recruitment will continue until the target is reached, estimated to be june 2013 sub-study: full title: (sub-study to oskira-4): a phase iib, multi-centre, randomised, double-blind, placebo-controlled, parallel group study of the efficacy and safety of fostamatinib disodium monotherapy compared with placebo or adalimumab monotherapy in patients with active rheumatoid arthritis: magnetic resonance imaging sub-study date: 21 march 2011 version: 1 primary objective: assess the efficacy of fostamatinib in reducing joint synovial disease activity as measured by: * change from baseline to week 6 (versus placebo) in omeract ramris synovitis score.

Eligibility criteria:
inclusion criteria: * male or female aged 18 and over * active rheumatoid arthritis (ra) diagnosed after the age of 16 and diagnosis within 5 years prior to study visit 1 and inadequate response to treatment with a maximum 2 disease-modifying anti-rheumatic drug (dmard) therapies, or diagnosis within 5 years prior to study visit 1 and intolerance to dmard therapy, or diagnosis within 2 years prior to study visit 1 and no previous use of dmards * 4 or more swollen joints and 4 or more tender/painful joints (from 28 joint count) and either erythrocyte sedimentation rate (esr) blood result of 28mm/h or more, or c-reactive protein (crp) blood result of 10mg/l or more * at least 2 of the following: documented history or current presence of positive rheumatoid factor (blood test), radiographic erosion within 12 months prior to study enrolment, presence of serum anti-cyclic citrullinated peptide antibodies (blood test) exclusion criteria: * females who are pregnant or breast feeding * poorly controlled hypertension * liver disease or significant liver function test abnormalities * certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders * recent or significant cardiovascular disease * significant active or recent infection including tuberculosis * previously received treatment with a tnf alpha antagonist (including etanercept, certolizumab, adalimumab, infliximab, golimumab) or anakinra or previous treatment with other biological agent including rituximab, abatacept and tocilizumab * use of any dmards within 6 weeks before first study visit * severe renal impairment * neutropenia

Keywords: rheumatoid arthritis oskira fostamatinib